Sinopharm Group Co. Ltd. (SHTDY)
USD 13.79
(0.0%)
USD 13.79
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 20.2 Billion CNY | -1.92% |
| 2022 | 20.6 Billion CNY | 4.53% |
| 2021 | 19.71 Billion CNY | 10.99% |
| 2020 | 17.75 Billion CNY | 10.06% |
| 2019 | 16.13 Billion CNY | 4.81% |
| 2018 | 15.39 Billion CNY | 29.32% |
| 2017 | 11.9 Billion CNY | 16.57% |
| 2016 | 10.21 Billion CNY | 11.39% |
| 2015 | 9.16 Billion CNY | 16.63% |
| 2014 | 7.86 Billion CNY | 28.84% |
| 2013 | 6.1 Billion CNY | 25.47% |
| 2012 | 4.86 Billion CNY | 33.75% |
| 2011 | 3.63 Billion CNY | 50.95% |
| 2010 | 2.4 Billion CNY | 55.38% |
| 2009 | 1.55 Billion CNY | 32.26% |
| 2008 | 1.17 Billion CNY | 48.49% |
| 2007 | 789.34 Million CNY | 64.36% |
| 2006 | 480.25 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 3.38 Billion CNY | -56.39% |
| 2024 Q2 | 5.12 Billion CNY | 51.39% |
| 2023 Q3 | 3.46 Billion CNY | -40.46% |
| 2023 FY | 20.2 Billion CNY | -1.92% |
| 2023 Q1 | 4.01 Billion CNY | -49.92% |
| 2023 Q4 | 7.76 Billion CNY | 124.11% |
| 2023 Q2 | 5.81 Billion CNY | 44.95% |
| 2022 Q4 | 8.01 Billion CNY | 126.92% |
| 2022 Q1 | 3.75 Billion CNY | -43.65% |
| 2022 FY | 20.6 Billion CNY | 4.53% |
| 2022 Q2 | 5.75 Billion CNY | 53.02% |
| 2022 Q3 | 3.53 Billion CNY | -38.6% |
| 2021 FY | 19.71 Billion CNY | 10.99% |
| 2021 Q3 | 5.23 Billion CNY | -10.58% |
| 2021 Q2 | 5.85 Billion CNY | 82.31% |
| 2021 Q4 | 6.67 Billion CNY | 27.37% |
| 2021 Q1 | 3.21 Billion CNY | -47.42% |
| 2020 Q2 | 5.03 Billion CNY | 97.43% |
| 2020 Q4 | 6.11 Billion CNY | 12.98% |
| 2020 Q3 | 5.4 Billion CNY | 7.51% |
| 2020 Q1 | 2.54 Billion CNY | -53.52% |
| 2020 FY | 17.75 Billion CNY | 10.06% |
| 2019 Q3 | 4.37 Billion CNY | -15.01% |
| 2019 FY | 16.13 Billion CNY | 4.81% |
| 2019 Q1 | 3.16 Billion CNY | -31.83% |
| 2019 Q2 | 5.15 Billion CNY | 62.83% |
| 2019 Q4 | 5.48 Billion CNY | 25.25% |
| 2018 Q2 | 4.53 Billion CNY | 71.77% |
| 2018 FY | 15.39 Billion CNY | 29.32% |
| 2018 Q1 | 2.64 Billion CNY | -27.06% |
| 2018 Q3 | 3.58 Billion CNY | -21.07% |
| 2018 Q4 | 4.64 Billion CNY | 29.5% |
| 2017 FY | 11.9 Billion CNY | 16.57% |
| 2017 Q3 | 3.62 Billion CNY | 23.29% |
| 2017 Q4 | 3.62 Billion CNY | 0.0% |
| 2017 Q1 | 2.93 Billion CNY | 17.94% |
| 2017 Q2 | 2.93 Billion CNY | 0.0% |
| 2016 Q1 | 2.44 Billion CNY | 6.57% |
| 2016 Q4 | 2.49 Billion CNY | 0.0% |
| 2016 Q3 | 2.49 Billion CNY | -9.92% |
| 2016 Q2 | 2.76 Billion CNY | 12.92% |
| 2016 FY | 10.21 Billion CNY | 11.39% |
| 2015 Q2 | 2.41 Billion CNY | 10.31% |
| 2015 Q3 | 2.29 Billion CNY | -5.0% |
| 2015 Q4 | 2.29 Billion CNY | 0.0% |
| 2015 FY | 9.16 Billion CNY | 16.63% |
| 2015 Q1 | 2.19 Billion CNY | 11.31% |
| 2014 FY | 7.86 Billion CNY | 28.84% |
| 2014 Q4 | 1.97 Billion CNY | 0.0% |
| 2014 Q3 | 1.97 Billion CNY | 0.78% |
| 2014 Q2 | 1.95 Billion CNY | 0.0% |
| 2014 Q1 | 1.95 Billion CNY | 26.77% |
| 2013 Q1 | 1.49 Billion CNY | 0.0% |
| 2013 FY | 6.1 Billion CNY | 25.47% |
| 2013 Q2 | 1.49 Billion CNY | 0.0% |
| 2013 Q4 | 1.54 Billion CNY | 0.0% |
| 2013 Q3 | 1.54 Billion CNY | 2.91% |
| 2012 FY | 4.86 Billion CNY | 33.75% |
| 2011 FY | 3.63 Billion CNY | 50.95% |
| 2010 FY | 2.4 Billion CNY | 55.38% |
| 2009 FY | 1.55 Billion CNY | 32.26% |
| 2008 FY | 1.17 Billion CNY | 48.49% |
| 2007 FY | 789.34 Million CNY | 64.36% |
| 2006 FY | 480.25 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| China Medicine Corporation | 12.26 Million USD | -164653.918% |
| DH Enchantment Inc. | -145.23 Thousand USD | 13914541.025% |
| Exlites Holdings International, Inc. | -15.49 Thousand USD | 130466174.887% |
| Itonis, Inc. | -38.31 Thousand USD | 52751848.891% |
| One Step Vending Corp. | -27.79 Thousand USD | 72721204.714% |
| MediPal Holdings Corporation | 312.71 Million USD | -6362.477% |
| PD-Rx Pharmaceuticals, Inc. | -190.47 Thousand USD | 10609882.283% |
| Pharmagen, Inc. | -2159.03 USD | 936031326.986% |
| Suzuken Co., Ltd. | 230.42 Million USD | -8670.372% |